News & Updates
Updates, press releases, and news on our work on GB-13.
Penn State University College of Medicine, Department of Neurosurgery and Targepeutics are pleased to announce that they have been awarded a W.W. Smith Charitable Trust Medical grant. This grant will…
Read MoreTargepeutics is presenting the latest efficacy data related to treatment of GBM and DMG tumors with the novel immunotoxin, GB13. This data is presented as a poster presentation during the…
Read MoreTargepeutics announces a Phase I Small Business Innovation Research (SBIR) grant awarded to Dr Randy Schrecengost as Primary Investigator to support preliminary data demonstrating that GB13 can specifically target IL13Rα2-positive…
Read MoreA poster presentation, entitled LOCO-REGIONAL INFUSION OF GB-13 (IL13.E13K-PE4E) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT HIGH-GRADE GLIOMA is presented at the SNO 2022 Annual Clinical Trials and Brain Metastases…
Read More